Espec Corp.
【Espec】Revision of Capital Cost and Mid-term Management Plan｜May 2026
Espec has revised its capital cost to 10% and set its ROE target for the mid-term management plan at over 12.0%. Although the ROE for FY2025 was 10.0% and did not meet the target, the stock price is considered undervalued.
Key Figures
- Net Sales: 70,034 million yen (FY2026)
- ROE: 10.0% (FY2025)
- Capital Cost: Revised to 10%
AI要約
Performance Overview
Espec revised its capital cost from the conventional 8% to 10% at the Board of Directors meeting in May 2026, setting its ROE target at over 12.0%. Although the ROE for FY2025 was 10.0%, failing to meet the target, net sales increased to 70,034 million yen, up 4.2% from the previous year. Net income was 5,879 million yen, showing a slight decline. The stock price remains undervalued, and the company is advancing its mid- to long-term growth strategy and strengthening IR activities.
Future Outlook and Strategies
Espec has revised its mid-term management plan 'PROGRESSIVE PLUS 2027,' aiming for net sales of 76 billion yen, operating profit of 9.1 billion yen, and ROE of over 12.0% in FY2027. While emphasizing capital efficiency, the company is proactively promoting growth investments and shareholder returns, maintaining a healthy financial position with a debt-to-equity ratio controlled within 70%. Furthermore, it is focusing on expanding revenue through areas such as AI semiconductors, autonomous driving, and satellite communications, while also strengthening IR activities.
Espec Corporation
Company overview · Stock price · Financial data · All IR
